Great West Life Assurance Co. Can Holds Holdings in Insulet Corporation (PODD)

Great West Life Assurance Co. Can held its position in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,535 shares of the medical instruments supplier’s stock at the end of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in Insulet Corporation were worth $283,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its holdings in shares of Insulet Corporation by 0.4% in the first quarter. FMR LLC now owns 8,647,651 shares of the medical instruments supplier’s stock valued at $372,628,000 after purchasing an additional 33,745 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Insulet Corporation by 4.2% in the first quarter. Vanguard Group Inc. now owns 4,556,847 shares of the medical instruments supplier’s stock valued at $196,355,000 after purchasing an additional 184,465 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Insulet Corporation by 7,285.2% in the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after purchasing an additional 4,137,326 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Insulet Corporation by 64.2% in the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock valued at $102,521,000 after purchasing an additional 930,062 shares during the last quarter. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of Insulet Corporation by 11.9% in the first quarter. Frontier Capital Management Co. LLC now owns 1,759,454 shares of the medical instruments supplier’s stock valued at $75,815,000 after purchasing an additional 187,577 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This piece was reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2017/09/13/great-west-life-assurance-co-can-holds-holdings-in-insulet-corporation-podd.html.

In other Insulet Corporation news, EVP Charles Alpuche acquired 2,500 shares of Insulet Corporation stock in a transaction on Wednesday, September 6th. The stock was purchased at an average price of $58.08 per share, for a total transaction of $145,200.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by corporate insiders.

Insulet Corporation (NASDAQ PODD) opened at 58.65 on Wednesday. The firm’s 50-day moving average is $54.94 and its 200-day moving average is $47.23. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $59.97. The company’s market capitalization is $3.41 billion.

Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $110.00 million during the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. Insulet Corporation’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) EPS. On average, equities research analysts forecast that Insulet Corporation will post ($0.50) EPS for the current year.

Several equities analysts recently weighed in on PODD shares. Jefferies Group LLC reissued a “buy” rating and issued a $58.00 target price (up from $48.00) on shares of Insulet Corporation in a research note on Wednesday, August 9th. Northland Securities reissued a “buy” rating on shares of Insulet Corporation in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $55.00 target price on shares of Insulet Corporation and gave the company a “hold” rating in a research note on Friday, August 4th. BidaskClub raised shares of Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th. Finally, Cowen and Company reissued an “outperform” rating and issued a $63.00 target price (up from $52.00) on shares of Insulet Corporation in a research note on Friday, August 4th. Eight equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $50.46.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply